Compare DFDV & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DFDV | LIXT |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | 16 | 3 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.4M | 107.6M |
| IPO Year | N/A | N/A |
| Metric | DFDV | LIXT |
|---|---|---|
| Price | $2.93 | $7.45 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $45.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 412.0K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.58 | N/A |
| Revenue Next Year | $23.65 | N/A |
| P/E Ratio | $0.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.44 | $1.28 |
| 52 Week High | $32.00 | $8.25 |
| Indicator | DFDV | LIXT |
|---|---|---|
| Relative Strength Index (RSI) | 43.41 | 58.00 |
| Support Level | $2.61 | $3.82 |
| Resistance Level | $5.22 | $7.64 |
| Average True Range (ATR) | 0.29 | 0.74 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 35.97 | 66.74 |
DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.